Vol 17, No 2 (2020)
Prace poglądowe - nadesłane
Get Citation

Venlafaxine XR, clinical use of higher doses ( > 150 mg)

Paweł Mierzejewski
DOI: 10.5603/PSYCH.2020.0014
·
Psychiatria 2020;17(2):76-79.

paid access

Vol 17, No 2 (2020)
Prace poglądowe - nadesłane

Abstract

This paper discusses the dual serotonergic-noradrenergic mechanism of action of venlafaxine, its indications for use, and dosage. Special attention was paid to the clinical application of higher doses of the drug, above 150 mg in the treatment of depression and anxiety disorders. Venlafaxine is one of the most effective antidepressants. The maximum recommended dose is 225 mg/day for anxiety disorders and 375 mg/day for major depression. The use of higher doses of the drug allows to take full advantage of its dual mechanism of action and improve its effectiveness.

Abstract

This paper discusses the dual serotonergic-noradrenergic mechanism of action of venlafaxine, its indications for use, and dosage. Special attention was paid to the clinical application of higher doses of the drug, above 150 mg in the treatment of depression and anxiety disorders. Venlafaxine is one of the most effective antidepressants. The maximum recommended dose is 225 mg/day for anxiety disorders and 375 mg/day for major depression. The use of higher doses of the drug allows to take full advantage of its dual mechanism of action and improve its effectiveness.

Get Citation
About this article
Title

Venlafaxine XR, clinical use of higher doses (> 150 mg)

Journal

Psychiatria (Psychiatry)

Issue

Vol 17, No 2 (2020)

Pages

76-79

DOI

10.5603/PSYCH.2020.0014

Bibliographic record

Psychiatria 2020;17(2):76-79.

Authors

Paweł Mierzejewski

References (13)
  1. Grostowicz A, Siwek M. Wenlafaksyna- właściwości farmakologiczne oraz zastosowanie w praktyce klinicznej. Medycyna Faktów. 2180; 11(3): 1–3.
  2. Cipriani A, Furukawa TA, Salanti G, et al. Multiple Meta-Analyses of New Generation Antidepressants (MANGA) Study Group. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391((10128)): 1357–1366.
  3. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373(9665): 746–758.
  4. Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol. 2006; 26(3): 250–258.
  5. Kıvrak Y, Güvenç TS, Akbulut N, et al. Accelerated hypertension after venlafaxine usage. Case Rep Psychiatry. 2014; 2014: 659715.
  6. Ballenger JC. Clinical evaluation of venlafaxine. J Clin Psychopharmacol. 1996; 16(3 Suppl 2): 29S–35S; discussion 35S.
  7. Ellingrod VL, Perry PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm. 1994; 51(24): 3033–3046.
  8. Jarema M. Standardy leczenia farmaklgiczneg niektórych zaburzeń psychicznych. Via Medica, Gdańsk 2015.
  9. Debonnel G, Saint-André E, Hébert C, et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol. 2007; 10(1): 51–61.
  10. Owens MJ, Krulewicz S, Simon JS, et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology. 2008; 33(13): 3201–3212.
  11. Święcicki L. Stosowanie wenlafaksyny w dawkach większych niż 225 mg na dobę. Bilans ryzyka i korzyści. Psychiatr Psychol Klin. 2015; 15 (1): 41–44.
  12. Vermeiden M, Mulder PG, van den Broek WW, et al. A double-blind randomized study comparing plasma level-targeted dose imipramine and high-dose venlafaxine in depressed inpatients. J Psychiatr Res. 2013; 47(10): 1337–1342.
  13. Klamerus KJ, Parker VD, Rudolph RL, et al. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy. 1996; 16(5): 915–923.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Psychiatria dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl